303 related articles for article (PubMed ID: 30297804)
21. Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer.
Matsumoto M; Seike M; Noro R; Soeno C; Sugano T; Takeuchi S; Miyanaga A; Kitamura K; Kubota K; Gemma A
BMC Cancer; 2015 Apr; 15():241. PubMed ID: 25884680
[TBL] [Abstract][Full Text] [Related]
22. Phosphorylation of initiation factor 4E is resistant to SB203580 in cells expressing a drug-resistant mutant of stress-activated protein kinase 2a/p38.
Morley SJ; Naegele S
Cell Signal; 2003 Aug; 15(8):741-9. PubMed ID: 12781867
[TBL] [Abstract][Full Text] [Related]
23. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
Liu Y; Sun L; Su X; Guo S
Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474
[TBL] [Abstract][Full Text] [Related]
25. Pro-inflammatory cytokine release in keratinocytes is mediated through the MAPK signal-integrating kinases.
Kjellerup RB; Kragballe K; Iversen L; Johansen C
Exp Dermatol; 2008 Jun; 17(6):498-504. PubMed ID: 18081851
[TBL] [Abstract][Full Text] [Related]
26. MNK1 inhibitor as an antiviral agent suppresses buffalopox virus protein synthesis.
Kumar R; Khandelwal N; Chander Y; Riyesh T; Tripathi BN; Kashyap SK; Barua S; Maherchandani S; Kumar N
Antiviral Res; 2018 Dec; 160():126-136. PubMed ID: 30393013
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor.
Evans JF; Rue RW; Mukhitov AR; Obraztsova K; Smith CJ; Krymskaya VP
Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31878201
[TBL] [Abstract][Full Text] [Related]
28. Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway.
Liu Z; Li Y; Lv C; Wang L; Song H
Biochem Biophys Res Commun; 2016 Sep; 478(2):893-9. PubMed ID: 27520370
[TBL] [Abstract][Full Text] [Related]
29. MNK kinases facilitate c-myc IRES activity in rapamycin-treated multiple myeloma cells.
Shi Y; Frost P; Hoang B; Yang Y; Fukunaga R; Gera J; Lichtenstein A
Oncogene; 2013 Jan; 32(2):190-7. PubMed ID: 22370634
[TBL] [Abstract][Full Text] [Related]
30. Regulation of eukaryotic initiation factor 4E (eIF4E) phosphorylation by mitogen-activated protein kinase occurs through modulation of Mnk1-eIF4G interaction.
Shveygert M; Kaiser C; Bradrick SS; Gromeier M
Mol Cell Biol; 2010 Nov; 30(21):5160-7. PubMed ID: 20823271
[TBL] [Abstract][Full Text] [Related]
31. Induction of MNK Kinase-dependent eIF4E Phosphorylation by Inhibitors Targeting BET Proteins Limits Efficacy of BET Inhibitors.
Pham TND; Kumar K; DeCant BT; Shang M; Munshi SZ; Matsangou M; Ebine K; Munshi HG
Mol Cancer Ther; 2019 Feb; 18(2):235-244. PubMed ID: 30446586
[TBL] [Abstract][Full Text] [Related]
32. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.
Lim S; Saw TY; Zhang M; Janes MR; Nacro K; Hill J; Lim AQ; Chang CT; Fruman DA; Rizzieri DA; Tan SY; Fan H; Chuah CT; Ong ST
Proc Natl Acad Sci U S A; 2013 Jun; 110(25):E2298-307. PubMed ID: 23737503
[TBL] [Abstract][Full Text] [Related]
33. Rapamycin enhances eIF4E phosphorylation by activating MAP kinase-interacting kinase 2a (Mnk2a).
Stead RL; Proud CG
FEBS Lett; 2013 Aug; 587(16):2623-8. PubMed ID: 23831578
[TBL] [Abstract][Full Text] [Related]
34. Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cells.
Eckerdt F; Beauchamp E; Bell J; Iqbal A; Su B; Fukunaga R; Lulla RR; Goldman S; Platanias LC
Oncotarget; 2014 Sep; 5(18):8442-51. PubMed ID: 25193863
[TBL] [Abstract][Full Text] [Related]
35. First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines.
Ramalingam S; Gediya L; Kwegyir-Afful AK; Ramamurthy VP; Purushottamachar P; Mbatia H; Njar VC
Oncotarget; 2014 Jan; 5(2):530-43. PubMed ID: 24504069
[TBL] [Abstract][Full Text] [Related]
36. Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors.
Dreas A; Mikulski M; Milik M; Fabritius CH; Brzózka K; Rzymski T
Curr Med Chem; 2017; 24(28):3025-3053. PubMed ID: 28164761
[TBL] [Abstract][Full Text] [Related]
37. TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling.
Martin P; Wagh V; Reis SA; Erdin S; Beauchamp RL; Shaikh G; Talkowski M; Thiele E; Sheridan SD; Haggarty SJ; Ramesh V
Mol Autism; 2020; 11(1):2. PubMed ID: 31921404
[TBL] [Abstract][Full Text] [Related]
38. Mnk1 and 2 are dispensable for T cell development and activation but important for the pathogenesis of experimental autoimmune encephalomyelitis.
Gorentla BK; Krishna S; Shin J; Inoue M; Shinohara ML; Grayson JM; Fukunaga R; Zhong XP
J Immunol; 2013 Feb; 190(3):1026-37. PubMed ID: 23269249
[TBL] [Abstract][Full Text] [Related]
39. Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway.
Chen C; Cheng CD; Wu H; Wang ZW; Wang L; Jiang ZR; Wang AL; Hu C; Dong YF; Niu WX; Qi S; Qi ZP; Liu J; Wang WC; Niu CS; Liu QS
Acta Pharmacol Sin; 2021 Jan; 42(1):108-114. PubMed ID: 32398685
[TBL] [Abstract][Full Text] [Related]
40. Posttranscriptional regulation of TNFalpha expression via eukaryotic initiation factor 4E (eIF4E) phosphorylation in mouse macrophages.
Andersson K; Sundler R
Cytokine; 2006 Jan; 33(1):52-7. PubMed ID: 16431125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
